EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Focal Update on Immunotherapy and Liver Transplantation in the Era of Transplant Oncology

Maen Abdelrahim, Abdullah Esmail iD, Taizo Hibi, Vincenzo Mazzaferro

Current Oncology · 28.08.2024 · 31 (9) · 5021-5026

DOI: 10.3390/curroncol31090371 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 28.08.2024. Verfasst von Maen Abdelrahim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Section of GI Oncology, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Liver Transplantation, Immunotherapy, Liver Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transplant oncology is an expanding area of cancer therapy that specifically emphasizes the use of liver transplantation (LT) as the preferred treatment for patients with manageable, but unresectable, tumors. The management and optimization of overall survival strategies, accompanied by an arguably decent quality of life, have been at the forefront of liver oncology treatment, as a plurality of all primary liver cancers are identified as either hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA), which are classified as highly aggressive malignancies and frequently remain asymptomatic until they progress to advanced stages, rendering curative procedures, such as resection, impractical. This has led to an increase in utilization of neoadjuvant interventions conducted prior to surgery, which has yielded favorable outcomes. Though this treatment modality has prompted further investigations into the efficacy of immune checkpoint inhibitors (ICPIs) as standalone treatments and in combination with locoregional treatments (LRTs) to bridge more patients into curative eligibility. This multidisciplinary methodology and treatment planning has seen multiple successful trials of immunotherapy regimes and combinate treatments, setting the groundwork for increasing eligibility through downstaging and “bridging” previously ineligible patients within stringent LT criteria. Surveillance after LT is a crucial component of transplant oncology. The emergence of circulating tumor DNA (ctDNA) has provided a novel approach to identifying the recurrence of cancer in its early stages. Recent research has focused on liquid biopsy, a technique that effectively identifies the dynamics of cancer. This is another innovation to demonstrate the rate at which transplant oncology is rapidly advancing, making the focus of care feel disorienting. Modalities of care are constantly evolving, but when a field is changing as rapidly as this one, it is imperative to reorient to the data and the needs of the patients. In this commentary, we reflect on the update’s utilization of ICPIs in neoadjuvant settings as well as the updates on the utilization of liquid biopsy in post-LT follow-up surveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationImmunotherapyLiver NeoplasmsHumansCarcinoma, Hepatocellular

Stichwörter der Autor:innen

ctDNAimmunotherapyliver transplantationtransplant oncology

Autor:innen und Institutionen

  • Section of GI Oncology, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX 77030, USA.
  • Weill Cornell Medical College, New York, NY 10065, USA.
  • Cockrell Center for Advanced Therapeutic Phase I Program, Houston Methodist Research Institute, Houston, TX 77030, USA.
  • Department of Pediatric Surgery and Transplantation, Kumamoto University Graduate School of Medical Sciences, Kumamoto 862-0976, Japan.
  • Department of Oncology, University of Milan, 20122 Milan, Italy.
  • Gastro-Intestinal Surgery and Liver Transplantation Unit, The Istituto Nazionale dei Tumori (National Cancer Institute) of Milan, 20133 Milan, Italy.

ORCID-Profile: Abdullah Esmail

Zitieren

APA

Abdelrahim, M., Esmail, A., Hibi, T., & Mazzaferro, V. (2024). Focal Update on Immunotherapy and Liver Transplantation in the Era of Transplant Oncology. Current Oncology, 31(9), 5021-5026. https://doi.org/10.3390/curroncol31090371

Vancouver

Abdelrahim M, Esmail A, Hibi T, Mazzaferro V. Focal Update on Immunotherapy and Liver Transplantation in the Era of Transplant Oncology. Current Oncology. 2024;31(9):5021-5026. doi:10.3390/curroncol31090371

BibTeX
@article{Abdelrahim2024,
  author = {Abdelrahim, Maen and Esmail, Abdullah and Hibi, Taizo and Mazzaferro, Vincenzo},
  title = {Focal Update on Immunotherapy and Liver Transplantation in the Era of Transplant Oncology},
  journal = {Current Oncology},
  year = {2024},
  volume = {31},
  number = {9},
  pages = {5021--5026},
  doi = {10.3390/curroncol31090371}
}
Kostenlos starten →